Compare BRBI & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBI | LAB |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | Brazil | United States |
| Employees | 188 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.2M | 326.2M |
| IPO Year | N/A | 2008 |
| Metric | BRBI | LAB |
|---|---|---|
| Price | $11.45 | $0.89 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.35 |
| AVG Volume (30 Days) | 2.0K | ★ 2.5M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 61.54 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $101,937,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | $2.63 |
| P/E Ratio | $11.72 | ★ $2.68 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.90 | $0.70 |
| 52 Week High | $67.01 | $1.72 |
| Indicator | BRBI | LAB |
|---|---|---|
| Relative Strength Index (RSI) | 41.33 | 51.09 |
| Support Level | $10.90 | $0.79 |
| Resistance Level | $15.06 | $1.01 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 20.15 | 72.44 |
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.